Moctar Tokèda Abdoul Zeba1, Mahamoudou Sanou2, Cyrille Bisseye3, Alice Kiba2, Bolni Marius Nagalo1, Florencia Wendkuuni Djigma1, Tegwindé Rebecca Compaoré1, Yacouba Koumpingnin Nebié2, Kisito Kienou2, Tani Sagna1, Virginio Pietra4, Rémy Moret1, Jacques Simporé5. 1. "Pietro Annigoni" Biomolecular Research Centre (CERBA)/Labiogene, UFR/SVT, University of Ouagadougou, Ouagadougou, Gabon. 2. National Blood Transfusion Centre (CNTS), Ouagadougou, Gabon. 3. "Pietro Annigoni" Biomolecular Research Centre (CERBA)/Labiogene, UFR/SVT, University of Ouagadougou, Ouagadougou, Gabon Department of Biology, University of Sciences and Techniques of Masuku (USTM), Franceville, Gabon. 4. "Saint Camille" Medical Centre, Ouagadougou, Burkina Faso, Gabon. 5. "Pietro Annigoni" Biomolecular Research Centre (CERBA)/Labiogene, UFR/SVT, University of Ouagadougou, Ouagadougou, Gabon "Saint Camille" Medical Centre, Ouagadougou, Burkina Faso, Gabon.
Abstract
BACKGROUND: Hepatitis C virus (HCV) is responsible for about 900 deaths every year in Burkina Faso. In this country, serological screening for hepatitis B and C viruses is only carried out systematically among blood donors. The aim of this study was to determine the prevalence and genotypes of HCV among blood donors using reverse transcription polymerase chain reaction (PCR) and real-time PCR, respectively. MATERIALS AND METHODS: Serum samples were screened for antibodies to HCV using an enzyme-linked immunosorbent assay (ARCHITECT-i1000SR-ABBOTT). All the reactive samples for HCV antibodies were re-tested using a second enzyme-linked immunosorbent assay (Bio-Rad, Marnes la Coquette, France) for confirmation. RNA was detected in all the reactive samples for antibodies to HCV. HCV RNA positive samples were genotyped using the HCV Real-TM Genotype kit (Sacace Biotechnologies, Italy). RESULTS: Among 2,200 blood donors, the prevalences of antibodies to HCV and viral RNA were 4.4% (95% confidence interval=3.5-5.3) and 1.5% (95% confidence interval=1.0-2.0), respectively. Among HCV RNA carriers, genotyping showed that HCV genotypes 2 and 3 were the most prevalent as they were detected in 18 (56.3%) and 5 (15.6%) individuals, respectively. HCV genotypes 1a and 4 were the least frequent among the blood donors. HCV mixed genotypes 2/3 and 2/4 were also detected among the blood donors. CONCLUSION: The prevalence of HCV found in this study is lower than previously reported prevalences. Large-scale studies are needed to obtain a better picture of the molecular epidemiology of HCV in Burkina Faso.
BACKGROUND:Hepatitis C virus (HCV) is responsible for about 900 deaths every year in Burkina Faso. In this country, serological screening for hepatitis B and C viruses is only carried out systematically among blood donors. The aim of this study was to determine the prevalence and genotypes of HCV among blood donors using reverse transcription polymerase chain reaction (PCR) and real-time PCR, respectively. MATERIALS AND METHODS: Serum samples were screened for antibodies to HCV using an enzyme-linked immunosorbent assay (ARCHITECT-i1000SR-ABBOTT). All the reactive samples for HCV antibodies were re-tested using a second enzyme-linked immunosorbent assay (Bio-Rad, Marnes la Coquette, France) for confirmation. RNA was detected in all the reactive samples for antibodies to HCV. HCV RNA positive samples were genotyped using the HCV Real-TM Genotype kit (Sacace Biotechnologies, Italy). RESULTS: Among 2,200 blood donors, the prevalences of antibodies to HCV and viral RNA were 4.4% (95% confidence interval=3.5-5.3) and 1.5% (95% confidence interval=1.0-2.0), respectively. Among HCV RNA carriers, genotyping showed that HCV genotypes 2 and 3 were the most prevalent as they were detected in 18 (56.3%) and 5 (15.6%) individuals, respectively. HCV genotypes 1a and 4 were the least frequent among the blood donors. HCV mixed genotypes 2/3 and 2/4 were also detected among the blood donors. CONCLUSION: The prevalence of HCV found in this study is lower than previously reported prevalences. Large-scale studies are needed to obtain a better picture of the molecular epidemiology of HCV in Burkina Faso.
Authors: D Jeannel; C Fretz; Y Traore; N Kohdjo; A Bigot; E Pê Gamy; G Jourdan; K Kourouma; G Maertens; F Fumoux; J J Fournel; L Stuyver Journal: J Med Virol Date: 1998-06 Impact factor: 2.327
Authors: H Tokita; H Okamoto; H Iizuka; J Kishimoto; F Tsuda; L A Lesmana; Y Miyakawa; M Mayumi Journal: J Gen Virol Date: 1996-02 Impact factor: 3.891
Authors: Beenu Thakral; Neelam Marwaha; Y K Chawla; Karan Saluja; Arpita Sharma; R R Sharma; R W Minz; S K Agnihotri Journal: Indian J Med Res Date: 2006-10 Impact factor: 2.375
Authors: P Simmonds; E C Holmes; T A Cha; S W Chan; F McOmish; B Irvine; E Beall; P L Yap; J Kolberg; M S Urdea Journal: J Gen Virol Date: 1993-11 Impact factor: 3.891
Authors: G R Ndong-Atome; M Makuwa; O Ouwe-Missi-Oukem-Boyer; O G Pybus; M Branger; S Le Hello; S B Boye-Cheik; F Brun-Vezinet; M Kazanji; P Roques; S Bisser Journal: J Med Virol Date: 2008-09 Impact factor: 2.327
Authors: Nicolas Meda; Edouard Tuaillon; Dramane Kania; Adama Tiendrebeogo; Amandine Pisoni; Sylvie Zida; Karine Bollore; Isaïe Medah; Didier Laureillard; Jean Pierre Moles; Nicolas Nagot; Koumpingnin Yacouba Nebie; Philippe Van de Perre; Pierre Dujols Journal: Bull World Health Organ Date: 2018-08-29 Impact factor: 9.408
Authors: Joseph C Forbi; David S Campo; Michael A Purdy; Zoya E Dimitrova; Pavel Skums; Guo-liang Xia; Lili T Punkova; Lilia M Ganova-Raeva; Gilberto Vaughan; Yousr Ben-Ayed; William M Switzer; Yury E Khudyakov Journal: J Med Virol Date: 2014-02-12 Impact factor: 2.327